Moreover, since metabolic dysregulation is one of the main features of BC [145], Liao et al. performed metabolic profiling and a gene expression analysis, comparing TNBC and ER+ patient samples, as well as TNBC PDXs, to identify new therapeutic vulnerabilities. The gene discussed is ESR1; the disease is breast cancer.